Researchers Use PET to Visualize Cardiac Amyloidosis
By Andrew Deutsch Posted on 22 Nov 2016 |
Image: Researchers have demonstrated that F-18-florbetaben PET imaging can be used to accurately differentiate between cardiac amyloidosis and hypertensive heart disease (Photo courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia).
Results of a study have shown that a new non-invasive technique using PET imaging and a radiotracer, can visualize abnormal protein deposits in the heart, in a condition called cardiac amyloidosis.
The researchers used fluorine-18 (F-18)-florbetaben, a radioactive tracer, and Positron Emission Tomography (PET) to visualize and quantify the deposition of amyloid proteins in heart muscle. The technique could be used to diagnose cardiac amyloidosis accurately and non-invasively, and could also help clinicians the monitor disease burden.
The study results were published in the November 2016 issue of The Journal of Nuclear Medicine. The researchers from the Princess Alexandra Hospital (Brisbane, Australia) performed F-18-florbetaben PET in 14 subjects and compared patients who had thickened heart muscle, secondary to amyloid deposition, with those that had thickened myocardium as a result of hypertensive heart disease.
The researchers found a higher target-to-background Standardized Uptake Values (SUV) ratio and percentage myocardial radiotracer retention in amyloid patients compared to the control subjects with heart disease. The results show that the new PET technique can be used to identify and differentiate between patients with cardiac amyloidosis and those with hypertensive heart disease.
Corresponding author of the study, Dr. W. Phillip Law, said, "The first signs and symptoms of the disease are non-specific and usually attributed to other conditions. Currently, there is no definitive test to diagnose cardiac amyloidosis other than an invasive biopsy of the heart muscle. Cardiac amyloidosis is often not diagnosed until late in the course of the disease, as the typical appearance of the infiltrated myocardium on echocardiography and MRI can be mistaken for other more prevalent disorders. Tailored molecular imaging with PET using florbetaben may significantly simplify the diagnostic algorithm for patients with suspected cardiac amyloidosis. Future studies investigating florbetaben uptake pattern in other [non-amyloid, non-hypertensive] causes of heart muscle thickening would further clarify the specificity of florbetaben. The relationship of PET quantification of florbetaben retention in the heart, with histological amyloid plaque burden, may provide another means of monitoring disease and could also be useful in monitoring response of cardiac amyloid to treatment, but further research needs to be undertaken to investigate this relationship."
Related Links:
Princess Alexandra Hospital
The researchers used fluorine-18 (F-18)-florbetaben, a radioactive tracer, and Positron Emission Tomography (PET) to visualize and quantify the deposition of amyloid proteins in heart muscle. The technique could be used to diagnose cardiac amyloidosis accurately and non-invasively, and could also help clinicians the monitor disease burden.
The study results were published in the November 2016 issue of The Journal of Nuclear Medicine. The researchers from the Princess Alexandra Hospital (Brisbane, Australia) performed F-18-florbetaben PET in 14 subjects and compared patients who had thickened heart muscle, secondary to amyloid deposition, with those that had thickened myocardium as a result of hypertensive heart disease.
The researchers found a higher target-to-background Standardized Uptake Values (SUV) ratio and percentage myocardial radiotracer retention in amyloid patients compared to the control subjects with heart disease. The results show that the new PET technique can be used to identify and differentiate between patients with cardiac amyloidosis and those with hypertensive heart disease.
Corresponding author of the study, Dr. W. Phillip Law, said, "The first signs and symptoms of the disease are non-specific and usually attributed to other conditions. Currently, there is no definitive test to diagnose cardiac amyloidosis other than an invasive biopsy of the heart muscle. Cardiac amyloidosis is often not diagnosed until late in the course of the disease, as the typical appearance of the infiltrated myocardium on echocardiography and MRI can be mistaken for other more prevalent disorders. Tailored molecular imaging with PET using florbetaben may significantly simplify the diagnostic algorithm for patients with suspected cardiac amyloidosis. Future studies investigating florbetaben uptake pattern in other [non-amyloid, non-hypertensive] causes of heart muscle thickening would further clarify the specificity of florbetaben. The relationship of PET quantification of florbetaben retention in the heart, with histological amyloid plaque burden, may provide another means of monitoring disease and could also be useful in monitoring response of cardiac amyloid to treatment, but further research needs to be undertaken to investigate this relationship."
Related Links:
Princess Alexandra Hospital
Latest Nuclear Medicine News
- New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment